脂质体作为药物载体在心血管疾病中应用前景取决于:(1)脂质体在体内的稳定性;(2)脂质体能否选择性地与靶细胞作用;(3)脂质体携载的药物导入细胞内能否达到生物效应浓度而无毒副作用。本文结合我室工作,针对上述问题,综述了国内外的研究进展,阐明了脂质体作为药物载体导向治疗心血管疾病的实验依据。 The potential of liposomes as drug carriers for cardiovascular disease depends on: (1) the stability of the liposomes in vivo; (2) the ability of the liposomes to selectively interact with target cells; (3) Of the drug into the cell can reach the biological effect of concentration without toxic side effects. This article combined with my work in the room, aiming at the above problems, reviewed the research progress at home and abroad, and clarified the experimental basis of liposomes as drug carrier-oriented treatment of cardiovascular diseases.